PYC Therapeutics Says US Patent Office Grants Composition of Matter Patents for Three Drug Candidates

MT Newswires Live

Jul 08

PYC Therapeutics (ASX:PYC) said the US Patent Office granted composition of matter patents covering three of its drug candidates and extended the patent life for PYC-003 through to June 13, 2044, for PYC-001 through to April 10, 2043, and for VP-001 through to May 17, 2043, according to a Wednesday Australian bourse filing.

PYC-003 seeks to address the underlying cause of polycystic kidney disease, PYC-001 seeks to address autosomal dominant optic atrophy, and VP-001 seeks to address retinitis pigmentosa type 11, per the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2649955847"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649955847\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649955847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 07:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649955847","market":"nz","top_or_hot":-1,"title":"PYC Therapeutics Says US Patent Office Grants Composition of Matter Patents for Three Drug Candidates","media":"MT Newswires Live","content":"<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) said the US Patent Office granted composition of matter patents covering three of its drug candidates and extended the patent life for PYC-003 through to June 13, 2044, for PYC-001 through to April 10, 2043, and for <a href=\"https://laohu8.com/S/VP..UK\">VP</a>-001 through to May 17, 2043, according to a Wednesday Australian bourse filing.</p><p>PYC-003 seeks to address the underlying cause of polycystic kidney disease, PYC-001 seeks to address autosomal dominant optic atrophy, and VP-001 seeks to address retinitis pigmentosa type 11, per the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PYC Therapeutics Says US Patent Office Grants Composition of Matter Patents for Three Drug Candidates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPYC Therapeutics Says US Patent Office Grants Composition of Matter Patents for Three Drug Candidates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-08 07:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) said the US Patent Office granted composition of matter patents covering three of its drug candidates and extended the patent life for PYC-003 through to June 13, 2044, for PYC-001 through to April 10, 2043, and for <a href=\"https://laohu8.com/S/VP..UK\">VP</a>-001 through to May 17, 2043, according to a Wednesday Australian bourse filing.</p><p>PYC-003 seeks to address the underlying cause of polycystic kidney disease, PYC-001 seeks to address autosomal dominant optic atrophy, and VP-001 seeks to address retinitis pigmentosa type 11, per the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PYC.AU","symbol_name":"PYC THERAPEUTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2649955847","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649955847","pubTimestamp":1783467897,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PYC Therapeutics  said the US Patent Office granted composition of matter patents covering three of its drug candidates and extended the patent life for PYC-003 through to June 13, 2044, for PYC-001 through to April 10, 2043, and for VP-001 through to May 17, 2043, according to a Wednesday Australian bourse filing.PYC-003 seeks to address the underlying cause of polycystic kidney disease, PYC-001 seeks to address autosomal dominant optic atrophy, and VP-001 seeks to address retinitis pigmentosa type 11, per the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PYC.AU":"PYC THERAPEUTICS LTD","BK4539":"次新股","BK4139":"生物科技","BK7067":"生物科技","BK4007":"制药","LENZ":"Therapeutics"},"translate_title":"PYC Therapeutics表示美国专利局授予三种候选药物的物质成分专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYC.AU":1,"LENZ":1.5},"content_text":"PYC Therapeutics (ASX:PYC) said the US Patent Office granted composition of matter patents covering three of its drug candidates and extended the patent life for PYC-003 through to June 13, 2044, for PYC-001 through to April 10, 2043, and for VP-001 through to May 17, 2043, according to a Wednesday Australian bourse filing.PYC-003 seeks to address the underlying cause of polycystic kidney disease, PYC-001 seeks to address autosomal dominant optic atrophy, and VP-001 seeks to address retinitis pigmentosa type 11, per the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}